FrancophonIA/ELRC3.0 huggingface dataset:
English: • Medication errors due to switching between formulations (dispersible tablets and film-coated tablets/granules).
Slovenian: • napake pri odmerjanju zdravila pri prehajanju z ene formulacije zdravila na drugo (z disperzibilnih tablet na filmsko obložene tablete oziroma zrnca ali obratno).
English: Physicians and patients should remain alert for signs and symptoms of gastrointestinal ulceration and haemorrhage during EXJADE therapy and promptly initiate additional evaluation and treatment if a serious gastrointestinal adverse reaction is suspected.
Slovenian: Zdravniki in bolniki morajo biti ves čas zdravljenja z zdravilom EXJADE pozorni na znake in simptome ulceracij in krvavitev gastrointestinalnega trakta, v primeru suma na resen gastrointestinalni neželeni učinek pa nemudoma začeti z dodatnimi pregledi in zdravljenjem.
English: EXJADE 500 mg dispersible tablets are also available in multipacks containing 294 (3 packs of 98) dispersible tablets.
Slovenian: EXJADE 500 mg disperzibilne tablete so na voljo tudi v obliki skupnih pakiranj, ki vsebujejo 294 (3 pakiranja po 98) disperzibilnih tablet.
English: Non-interventional post-authorisation safety study (PASS): In order to assess the long-term exposure and safety of deferasirox dispersible and film-coated tablets, the MAH should conduct an observational cohort study in paediatric non-transfusion-dependent thalassaemia patients over 10 years old for whom deferoxamine is contraindicated or inadequate conducted according to a CHMP-agreed protocol.
Slovenian: Neintervencijska varnostna študija po odobritvi zdravila (post-authorisation safety study, PASS): Za oceno dolgotrajnega zdravljenja in varnosti uporabe tako disperzibilnih kot filmsko obloženih tablet mora imetnik dovoljenja za promet z zdravilom po protokolu, ki ga odobri odbor CHMP, izvesti opazovalno kohortno študijo pri pediatričnih bolnikih s talasemijo, neodvisno od transfuzij, ki so stari nad 10 let in za katere je zdravljenje s deferoksaminom kontraindicirano ali neprimerno.
English: The tablet coating material contains: hypromellose; titanium dioxide (E171); macrogol (4000); talc; indigo carmine aluminium lake (E132).
Slovenian: Obloga tablete vsebuje: hipromelozo, titanov dioksid (E171), makrogol (4000), smukec, indigotin (E132).
English: Dose adjustments may be made in steps of 5 to 10 mg/kg and are to be tailored to the individual patient's response and therapeutic goals (maintenance or reduction of iron burden).
Slovenian: Prilagajanje odmerka lahko poteka v korakih po 5 do 10 mg/kg, prirediti jih je potrebno odzivu in ciljem zdravljenja posameznega bolnika (vzdrževanje ali zmanjševanje obremenitve z železom).
English: EXJADE is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) (see section 5.2).
Slovenian: Uporaba zdravila EXJADE ni priporočena pri bolnikih s hudo okvaro jeter (Child-Pugh stopnje C) (glejte poglavje 5.2).
English: The overall exposure of adolescents (12 to ≤17 years) and children (2 to <12 years) to deferasirox after single and multiple doses was lower than that in adult patients.
Slovenian: (12 do ≤17 let) in otrocih (2 do <12 let) nižja kot pri odraslih bolnikih.
English: • Take EXJADE granules either with or without a light meal.
Slovenian: • Zrnca zdravila EXJADE vzemite bodisi z lahkim obrokom ali brez obroka.
English: • When serum creatinine is elevated and if another abnormality has been detected (e.g. proteinuria, signs of Fanconi syndrome).
Slovenian: • kadar je koncentracija kreatinina v serumu zvišana in se pokaže še druga nepravilnost (kot je proteinurija, znaki Fanconijevega sindroma);
English: 98 dispersible tablets.
Slovenian: 98 disperzibilnih tablet.
English: • The rules for treatment dose adjustments and interruption when target serum ferritin +/- liver iron concentration are reached.
Slovenian: • pravila za prilagajanje odmerka in prekinitev zdravljenja, kadar je dosežena ciljna koncentracija feritina v serumu skupaj z doseženo ciljno koncentracijo železa v jetrih ali brez nje;
English: • Description of available deferasirox formulations (e.g. dispersible tablets, film-coated tablets and granules) o Different posology regimen o Different conditions of administration o Dose conversion table when switching from one formulation to another
Slovenian: • opis formulacij zdravila z deferasiroksom (npr. disperzibilnih tablet, filmsko obloženih tablet in zrnc), ki so na voljo o različne režime odmerjanja o različne pogoje jemanja o preglednico za pretvorbo višine odmerkov pri prehodu z ene formulacije na drugo
English: Deferasirox should not be reintroduced in patients who have experienced a hypersensitivity reaction due to the risk of anaphylactic shock (see section 4.3).
Slovenian: Pri bolnikih, pri katerih se je pojavila preobčutljivostna reakcija, se deferasiroksa ne sme ponovno uvesti zaradi tveganja za nastanek anafilaktičnega šoka (glejte poglavje 4.3).
English: This includes in particular: - other iron chelators, which must not be taken with EXJADE, - antacids (medicines used to treat heartburn) containing aluminium, which should not be taken at the same time of day as EXJADE, - ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis), - simvastatin (used to lower cholesterol), - certain painkillers or anti-inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids), - oral bisphosphonates (used to treat osteoporosis), - anticoagulant medicines (used to prevent or treat blood clotting), - hormonal contraceptive agents (birth control medicines), - bepridil, ergotamine (used for heart problems and migraines), - repaglinide (used to treat diabetes), - rifampicin (used to treat tuberculosis), - phenytoin, phenobarbital, carbamazepine (used to treat epilepsy), - ritonavir (used in the treatment of HIV infection), - paclitaxel (used in cancer treatment), - theophylline (used to treat respiratory diseases such as asthma), - clozapine (used to treat psychiatric disorders such as schizophrenia), - tizanidine (used as a muscle relaxant), - cholestyramine (used to lower cholesterol levels in the blood), - busulfan (used as a treatment prior to transplantation in order to destroy the original bone marrow before the transplant).
Slovenian: ibuprofen, kortikosteroide), - difosfonate v obliki, ki jo zaužijete (za zdravljenje osteoporoze), - antikoagulante (za preprečevanje strjevanja krvi), - hormonska kontracepcijska sredstva (za uravnavanje rojstev), - bepridil, ergotamin (v primeru težav s srcem ali pri migreni), - repaglinid (za zdravljenje sladkorne bolezni), - rifampicin (za zdravljenje tuberkuloze), - fenitoin, fenobarbital, karbamazepin (za zdravljenje epilepsije), - ritonavir (za zdravljenje okužbe s HIV), - paklitaksel (za zdravljenje raka), - teofilin (za zdravljenje bolezni dihal, kot je astma), - klozapin (za zdravljenje psihiatričnih motenj, kot je shizofrenija), - tizanidin (mišični relaksant), - holestiramin (za zniževanje ravni holesterola v krvi), - busulfan (zdravilo, ki se uporablja pred presaditvijo za uničenje bolnikovega kostnega mozga pred prejemom presadka).
English: Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level.
Slovenian: Odmerki nad 40 mg/kg niso priporočljivi, saj so na voljo le omejene izkušnje z odmerki nad to vrednostjo.
English: In patients with a short life expectancy (e.g. high-risk myelodysplastic syndromes), especially when co-morbidities could increase the risk of adverse events, the benefit of EXJADE might be limited and may be inferior to risks.
Slovenian: Pri bolnikih z nižjo pričakovano življenjsko dobo (kot je na primer pri mielodisplastičnih sindromih z visokim tveganjem) je lahko korist, ki jo prinaša zdravilo EXJADE, omejena in ne dosega vedno ravni tveganja, zlasti kadar bi se zaradi drugih sočasno prisotnih bolezni lahko povečalo tveganje za neželene dogodke.
English: Bioavailability of deferasirox granules was 52% greater than that with dispersible tablets.
Slovenian: Biološka uporabnost deferasiroksa v obliki zrnc je bila za 52 % večja kot pri disperzibilnih tabletah.
English: Cardiac function should be monitored in patients with severe iron overload during long-term treatment with EXJADE.
Slovenian: Pri bolnikih s hudo preobremenitvijo z železom je treba med dolgotrajnim zdravljenjem z zdravilom EXJADE spremljati delovanje srca.
English: Although deferasirox has a lower affinity for aluminium than for iron, it is not recommended to take deferasirox granules with aluminium-containing antacid preparations.
Slovenian: Čeprav ima deferasiroks manjšo afiniteto do aluminija kot do železa, ni priporočljivo jemati zrnc z deferasiroksom sočasno z antacidi, ki vsebujejo aluminij.
English: PVC/PE/PVDC/Aluminium blisters.
Slovenian: PVC/PE/PVDC/aluminijski pretisni omoti
English: EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups: - in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (7 ml/kg/month of packed red blood cells) aged 2 to 5 years, - in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older, - in adult and paediatric patients with other anaemias aged 2 years and older.
Slovenian: Zdravilo EXJADE je indicirano tudi za zdravljenje kronične preobremenitve z železom zaradi transfuzij krvi v primerih, ko je zdravljenje z deferoksaminom kontraindicirano ali neprimerno pri naslednjih skupinah bolnikov: - pri pediatričnih bolnikih, ki imajo beta talasemijo major in preobremenitev z železom zaradi pogostih transfuzij krvi (7 ml/kg/mesec koncentriranih eritrocitov) in so stari od 2 do 5 let, - pri odraslih in pediatričnih bolnikih, ki imajo beta talasemijo major in preobremenitev z železom zaradi manj pogostih transfuzij krvi (<7 ml/kg/mesec koncentriranih eritrocitov) in so stari 2 leti ali več, - pri odraslih in pediatričnih bolnikih z drugimi anemijami, ki so stari 2 leti ali več.
English: When this results in a daily dose less than 20 mg/kg body weight, the patient's response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).
Slovenian: Če to pomeni dnevni odmerek, ki bi bil nižji od 20 mg/kg telesne mase, je treba spremljati bolnikov odziv in v primerih, ko ne pride do zadostne učinkovitosti, razmisliti o zvišanju odmerka (glejte poglavje 5.1).
English: Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated with EXJADE.
Slovenian: O renalni tubulopatiji so poročali večinoma pri otrocih in mladostnikih, ki so imeli beta talasemijo in so prejemali zdravilo EXJADE.
English: Stevens-Johnson syndrome1, hypersensitivity vasculitis1, urticaria1, erythema multiforme
Slovenian: Stevens-Johnsonov sindrom 1, preobčutljivostni vaskulitis urtikarija
English: 1, nephrolithiasis renal tubular necrosis General disorders and administration site conditions Uncommon:
Slovenian: 1, renalna tubularna nekroza Splošne težave in spremembe na mestu aplikacije občasni:
English: Not all pack sizes or strengths may be available in your country.
Slovenian: Morda na vašem trgu ni vseh navedenih pakiranj ali jakosti.
English: In a retrospective meta-analysis of 2,102 adult and paediatric beta-thalassaemia patients with transfusional iron overload treated with deferasirox dispersible tablets in two randomised and four open label studies of up to five years' duration, a mean creatinine clearance decrease of 13.2% in adult patients (95% CI: -14.4% to -12.1%; n=935) and 9.9% (95% CI: -11.1% to -8.6%; n=1,142) in paediatric patients was observed during the first year of treatment.
Slovenian: Očistek kreatinina pri preobremenitvi z železom zaradi transfuzij krvi V retrospektivni metaanalizi podatkov 2.102 odraslih in pediatričnih bolnikov z beta talasemijo in s preobremenitvijo z železom zaradi transfuzij krvi, ki so jih zdravili z deferasiroksom v obliki disperzibilnih tablet v okviru dveh randomiziranih kliničnih študij in štirih odprtih študij s trajanjem zdravljenja do pet let, so v prvem letu zdravljenja pri odraslih bolnikih opažali znižanje povprečne vrednosti očistka kreatinina za 13,2 % (95 % IZ: -14,4 % do -12,1 %; n=935), pri pediatričnih bolnikih pa za 9,9 % (95 % IZ: -11,1 % do -8,6 %; n=1.142).
English: • Paediatrics: either >ULN or creatinine clearance falls to <LLN at two consecutive visits.
Slovenian: • pri pediatričnih bolnikih: nad ZMN (zgornjo mejo normale) ali pa očistek kreatinina pade pod SMN pri dveh zaporednih obiskih;
English: Acid-base balance should be monitored as clinically indicated in these populations.
Slovenian: Pri navedenih skupinah bolnikov je potreben nadzor kislinsko-baznega ravnovesja v skladu s kliničnimi indikacijami.
English: Multipack: 294 (3 packs of 98) dispersible tablets.
Slovenian: Skupno pakiranje: 294 (3 pakiranja po 98) disperzibilnih tablet.
English: Titanium dioxide (E171) Macrogol (4000)
Slovenian: Sestavine obloge tablete: hipromeloza titanov dioksid (E171) makrogol (4000) smukec indigotin (E132)
English: Total exposure (AUC) was approximately doubled when taken along with a high-fat breakfast (fat content >50% of calories) and by about 50% when taken along with a standard breakfast.
Slovenian: Ob sočasnem zaužitju z maščobami bogatega zajtrka (vsebnost maščob >50 % kalorij) se je celotna izpostavljenost (AUC) približno podvojila, ob sočasnem zaužitju standardnega zajtrka pa se je povečala za okrog 50 %.
English: No clinical data on exposed pregnancies are available for deferasirox.
Slovenian: Za deferasiroks ni na voljo kliničnih podatkov od nosečnic, ki so bile izpostavljene zdravilu.
English: Taking EXJADE at the same time each day will also help you remember when to take your medicine.
Slovenian: Če boste jemali zdravilo EXJADE vsak dan ob istem času, tudi ne boste pozabili, kdaj ga morate vzeti.
English: The availability of long-term efficacy and safety data with EXJADE dispersible tablets used at doses above 30 mg/kg is currently limited (264 patients followed for an average of 1 year after dose escalation).
Slovenian: Zaenkrat še ni na voljo veliko podatkov o dolgoročni učinkovitosti in varnosti zdravila EXJADE v obliki disperzibilnih tablet v odmerkih nad 30 mg/kg (264 bolnikov so spremljali povprečno 1 leto po postopnem zviševanju odmerka).
English: Most reports of hepatic failure involved patients with significant morbidities including pre-existing liver cirrhosis.
Slovenian: večini poročil o odpovedi jeter je šlo za bolnike s pomembnimi boleznimi, med drugim z že prej prisotno cirozo jeter.
English: In an iron-balance metabolic study in iron-overloaded adult thalassaemic patients, deferasirox at daily doses of 10, 20 and 40 mg/kg (dispersible tablet formulation) induced the mean net excretion of 0.119, 0.329 and 0.445 mg Fe/kg body weight/day, respectively.
Slovenian: V presnovni študiji ravnovesja železa je pri odraslih bolnikih s talasemijo in preobremenitvijo z železom deferasiroks v dnevnem odmerku 10, 20 in 40 mg/kg (v obliki disperzibilnih tablet) povzročil povprečno neto ekskrecijo 0,119, 0,329 oziroma 0,445 mg Fe/kg telesne mase/dan.
English: STATEMENT OF ACTIVE SUBSTANCE(S)
Slovenian: Absolutna biološka uporabnost (AUC)
English: • Do not use any pack that is damaged or shows signs of tampering.
Slovenian: • Zdravila ne uporabljajte, če je ovojnina poškodovana ali opazite, da je bila že odprta.
English: After dose reduction, interrupt treatment, if Adult and paediatric Remains >33% above pre-treatment average and/or Decreases <LLN* (<90 ml/min)
Slovenian: prekinitev zdravljenja po znižanju odmerka , če: odrasli in pediatrični bolniki vrednost vztraja >33 % nad povprečjem vrednosti pred zdravljenjem in/ali znižanje pod spodnjo mejo normale (<90 ml/min)
English: Deferasirox also comes as “film-coated” tablets and granules.
Slovenian: Deferasiroks je na voljo tudi v obliki filmsko obloženih tablet in zrnc.
English: Unit packs containing 28, 84 or 252 dispersible tablets and multipacks containing 294 (3 packs of 98) dispersible tablets.
Slovenian: Posamezno pakiranje vsebuje 28, 84 ali 252 disperzibilnih tablet, skupno pakiranje pa vsebuje 294 (3 pakiranja po 98) disperzibilnih tablet.
English: Caution should be taken during chelation therapy to minimise the risk of overchelation in all patients (see section 4.4).
Slovenian: Pri vseh bolnikih je pri terapiji s kelacijo železa potrebna previdnost, da se čim bolj zmanjša tveganje za prekomerno kelacijo (glejte poglavje 4.4).
English: 300 (10 packs of 30) film-coated tablets
Slovenian: 300 (10 pakiranj po 30) filmsko obloženih tablet
English: For patients who are unable to swallow whole tablets, EXJADE film-coated tablets may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple).
Slovenian: Za bolnike, ki ne morejo pogoltniti celih tablet, je mogoče filmsko obložene tablete EXJADE zdrobiti in celoten odmerek primešati mehki hrani, na primer jogurtu ali jabolčni kaši.
English: • Adults and Paediatrics: remain >33% above baseline or creatinine clearance <LLN (90 ml/min)
Slovenian: • pri odraslih in pediatričnih bolnikih: ostane >33% nad izhodiščno vrednostjo ali pa očistek kreatinina ostane pod SMN (90 ml/min);
English: Clinical study in patients with non-transfusion-dependent thalassaemia syndromes In a 1-year study in patients with non-transfusion-dependent thalassaemia syndromes and iron overload (dispersible tablets at a dose of 10 mg/kg/day), diarrhoea (9.1%), rash (9.1%), and nausea (7.3%) were the most frequent study drug-related adverse events.
Slovenian: Klinične študije pri bolnikih s sindromi talasemije, neodvisnimi od transfuzij V enoletni študiji pri bolnikih, ki imajo preobremenitev z železom in katerega od sindromov talasemije, neodvisnih od transfuzij, (prejemali so disperzibilne tablete v odmerku 10 mg/kg/dan) so bili najbolj pogosti s študijskim zdravilom povezani neželeni dogodki naslednji: diareja (9,1 %), izpuščaj (9,1 %) in navzea (7,3 %).
English: The other ingredients are lactose monohydrate, crospovidone type A, povidone, sodium laurilsulfate, microcrystalline cellulose, colloidal anhydrous silica and magnesium stearate.
Slovenian: Druge sestavine zdravila so laktoza monohidrat, krospovidon tipa A, povidon, natrijev lavrilsulfat, mikrokristalna celuloza, brezvoden koloidni silicijev dioksid in magnezijev stearat.
English: >33% above pretreatment average and Decreases <LLN* (<90 ml/min)
Slovenian: >33 % nad povprečjem vrednosti pred zdravljenjem in znižanje pod spodnjo mejo normale (<90 ml/min)
English: Reduction of daily dose by 7 mg/kg/day (film-coated tablet formulation), if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes
Slovenian: - kasneje enkrat na mesec in enkrat na mesec znižanje dnevnega odmerka za 7 mg/kg/dan (v obliki filmsko obloženih tablet), če je znižanje navedenih parametrov ledvične funkcije prisotno pri dveh zaporednih obiskih in ga ni mogoče pripisati drugim vzrokom odrasli bolniki
English: Reduction of daily dose by 10 mg/kg/day (dispersible tablet formulation), if following renal parameters are observed at two consecutive visits and cannot be attributed to other causes
Slovenian: - kasneje enkrat na mesec in enkrat na mesec znižanje dnevnega odmerka za 10 mg/kg/dan (v obliki disperzibilnih tablet), če je znižanje navedenih parametrov ledvične funkcije prisotno pri dveh zaporednih obiskih in ga ni mogoče pripisati drugim vzrokom odrasli bolniki
English: EXJADE contains an active substance called deferasirox.
Slovenian: Zdravilo EXJADE vsebuje zdravilno učinkovino, ki jo imenujemo deferasiroks.
English: The most frequent reactions reported during chronic treatment with deferasirox dispersible tablets in adult and paediatric patients include gastrointestinal disturbances (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash.
Slovenian: Najpogostejši učinki, zabeleženi med kroničnim zdravljenjem z disperzibilnimi tabletami z deferasiroksom pri odraslih in pediatričnih bolnikih, vključujejo gastrointestinalne motnje (predvsem navzeo, bruhanje, diarejo ali bolečino v trebuhu) in kožni izpuščaj.
English: Daily treatment with the deferasirox dispersible tablet formulation at doses of 20 and 30 mg/kg for one year in frequently transfused adult and paediatric patients with beta-thalassaemia led to reductions in indicators of total body iron; liver iron concentration was reduced by about -0.4 and -8.9 mg Fe/g liver (biopsy dry weight (dw)) on average, respectively, and serum ferritin was reduced by about -36 and -926 µg/l on average, respectively.
Slovenian: Pri odraslih in pediatričnih bolnikih z beta talasemijo in s pogostimi transfuzijami je vsakodnevno zdravljenje z deferasiroksom v obliki disperzibilnih tablet z odmerki 20 in 30 mg/kg v obdobju enega leta povzročilo zmanjšanje kazalcev celotnega železa v organizmu: koncentracija železa v jetrih se je znižala v povprečju za približno 0,4 oziroma 8,9 mg Fe/g jeter (suhe teže bioptičnega materiala (suhe teže)), vrednost feritina v serumu pa se je v povprečju znižala za približno 36 oziroma 926 µg/l.
English: 84 dispersible tablets
Slovenian: 84 disperzibilnih tablet
English: • Prescribers - a letter including the following dossiers: o A prescribers' guide informing about the switch between formulations in order to address the important potential risk of medication error for deferasirox o A patient's guide informing about the possibility of co-existing formulations in the EU market, and the differences concerning their administration, in order to address the important potential risk of medication error for deferasirox Additionally, prescribers and pharmacists will be informed via a specific letter regarding the timelines for removing EXJADE dispersible tablets from the EU market.
Slovenian: • zdravniki, ki predpisujejo zdravilo - dopis, ki bo vključeval naslednje sklope: o navodila za predpisovalca z informacijami o prehajanju med formulacijami v opozorilo na pomembno tveganje za možne napake pri odmerjanju deferasiroksa, o navodila za bolnika z obvestilom o možni sočasni prisotnosti formulacij na trgu Evropske skupnosti in z opisom razlik pri odmerjanju obeh formulacij in opozorilom na pomembno tveganje za možne napake pri odmerjanju deferasiroksa.
English: • Monthly thereafter o The need to reduce by 10 mg/kg the dose if serum creatinine rises:
Slovenian: o potrebnost zmanjšanja odmerka za 10 mg/kg, če se koncentracija kreatinina v serumu zviša:
English: If any SCAR is suspected, EXJADE should be discontinued immediately and should not be reintroduced.
Slovenian: V primeru suma na katerokoli hudo kožno reakcijo je treba zdravilo EXJADE bolniku takoj ukiniti, ponovno pa se mu ga ne sme več predpisati.
English: 10 mg/kg/day For adults not assessed and ≤2,000 µg/l
Slovenian: 10 mg/kg/dan pri odraslih ni ocenjeno in ≤2.000 µg/l pri pediatričnih bolnikih prekinitev zdravljenja
English: If you have taken too much EXJADE, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away.
Slovenian: Če ste vzeli večji odmerek zdravila EXJADE, kot bi smeli Če ste vzeli preveč zdravila EXJADE ali je vaše tablete pomotoma zaužil kdo drug, takoj pokličite zdravnika ali v bolnišnico.
English: >14 ml/kg/month of PRBC (approx. >4 units/month for an adult)
Slovenian: >14 ml/kg/mesec koncentriranih eritrocitov (približno >4 enote/mesec pri odraslem)
English: It traps and removes excess iron which is then excreted mainly in the stools.
Slovenian: Zdravilo EXJADE veže in odstrani presežno železo, ki se potem izloči večinoma z blatom.
English: Taking EXJADE at the same time each day will also help you remember when to take your tablets.
Slovenian: Če boste jemali tablete zdravila EXJADE vsak dan ob istem času, tudi ne boste pozabili, kdaj jih morate vzeti.